- Home
- DAWN vs VIRT Comparison
DAWN vs VIRT Comparison
Compare DAWN & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- VIRT
- Stock Information
- Founded
- DAWN 2018
- VIRT 2008
- Country
- DAWN United States
- VIRT United States
- Employees
- DAWN N/A
- VIRT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- VIRT Investment Bankers/Brokers/Service
- Sector
- DAWN Health Care
- VIRT Finance
- Exchange
- DAWN Nasdaq
- VIRT Nasdaq
- Market Cap
- DAWN 1.3B
- VIRT N/A
- IPO Year
- DAWN 2021
- VIRT 2015
- Fundamental
- Price
- DAWN $12.79
- VIRT $35.41
- Analyst Decision
- DAWN Strong Buy
- VIRT Buy
- Analyst Count
- DAWN 7
- VIRT 7
- Target Price
- DAWN $36.17
- VIRT $29.50
- AVG Volume (30 Days)
- DAWN 1.0M
- VIRT 947.9K
- Earning Date
- DAWN 10-30-2024
- VIRT 01-23-2025
- Dividend Yield
- DAWN N/A
- VIRT 2.71%
- EPS Growth
- DAWN N/A
- VIRT 23.01
- EPS
- DAWN N/A
- VIRT 1.98
- Revenue
- DAWN $101,953,000.00
- VIRT $1,910,017,000.00
- Revenue This Year
- DAWN N/A
- VIRT N/A
- Revenue Next Year
- DAWN $36.10
- VIRT $2.12
- P/E Ratio
- DAWN N/A
- VIRT $17.85
- Revenue Growth
- DAWN N/A
- VIRT 10.60
- 52 Week Low
- DAWN $11.94
- VIRT $16.02
- 52 Week High
- DAWN $18.07
- VIRT $38.45
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- VIRT 47.55
- Support Level
- DAWN $12.26
- VIRT $36.13
- Resistance Level
- DAWN $12.81
- VIRT $37.96
- Average True Range (ATR)
- DAWN 0.52
- VIRT 1.03
- MACD
- DAWN -0.05
- VIRT -0.37
- Stochastic Oscillator
- DAWN 28.94
- VIRT 30.81
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.